losartan has been researched along with Oligohydramnios in 5 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Oligohydramnios: A condition of abnormally low AMNIOTIC FLUID volume. Principal causes include malformations of fetal URINARY TRACT; FETAL GROWTH RETARDATION; GESTATIONAL HYPERTENSION; nicotine poisoning; and PROLONGED PREGNANCY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We describe the reversal of losartan-induced oligohydramnios at 27 weeks of gestation with subsequent development of fetal thrombosis and possible mechanism of action for this extremely rare in utero complication." | 7.73 | In utero losartan withdrawal and subsequent development of fetal inferior vena cava thrombosis. ( Bakkum, JN; Brost, BC; Johansen, KL; Johnston, BW; Watson, WJ, 2006) |
| " She had been taking losartan tablets before and during pregnancy." | 4.02 | Use of angiotensin II receptor blocker during pregnancy: A case report. ( Duan, MF; Huang, N; Song, CR; Wang, YM; Wei, Q; Zhang, L, 2021) |
| "We describe the reversal of losartan-induced oligohydramnios at 27 weeks of gestation with subsequent development of fetal thrombosis and possible mechanism of action for this extremely rare in utero complication." | 3.73 | In utero losartan withdrawal and subsequent development of fetal inferior vena cava thrombosis. ( Bakkum, JN; Brost, BC; Johansen, KL; Johnston, BW; Watson, WJ, 2006) |
| "We report a case of maternal exposure to the antihypertensive drug losartan during weeks 20-31 of pregnancy." | 3.71 | Losartan and fetal toxic effects. ( Hagiwara, A; Ijiri, R; Saji, H; Yamanaka, M, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wei, Q | 1 |
| Zhang, L | 1 |
| Duan, MF | 1 |
| Wang, YM | 1 |
| Huang, N | 1 |
| Song, CR | 1 |
| Gersak, K | 1 |
| Cvijic, M | 1 |
| Cerar, LK | 1 |
| Esposito, F | 1 |
| Galfetti, M | 1 |
| Lava, SA | 1 |
| Balestra, B | 1 |
| Bianchetti, MG | 1 |
| Bakkum, JN | 1 |
| Brost, BC | 1 |
| Johansen, KL | 1 |
| Johnston, BW | 1 |
| Watson, WJ | 1 |
| Saji, H | 1 |
| Yamanaka, M | 1 |
| Hagiwara, A | 1 |
| Ijiri, R | 1 |
5 other studies available for losartan and Oligohydramnios
| Article | Year |
|---|---|
Use of angiotensin II receptor blocker during pregnancy: A case report.
Topics: Adult; Angiotensin Receptor Antagonists; Female; Humans; Losartan; Nephrotic Syndrome; Oligohydramni | 2021 |
Angiotensin II receptor blockers in pregnancy: a report of five cases.
Topics: Abnormalities, Drug-Induced; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphe | 2009 |
Fetopathy probably associated to self-medication with a blocker of the renin-angiotensin system.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Antimalarials; Cesarean | 2011 |
In utero losartan withdrawal and subsequent development of fetal inferior vena cava thrombosis.
Topics: Angiotensin II Type 1 Receptor Blockers; Contraindications; Diabetes Mellitus, Type 2; Female; Fetal | 2006 |
Losartan and fetal toxic effects.
Topics: Adult; Antihypertensive Agents; Contraindications; Female; Fetal Death; Humans; Losartan; Oligohydra | 2001 |